World Bispecific and T-Cell Engager Summit South Korea

Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. At the same time, the field is rapidly evolving beyond first-generation designs, with innovations in co-stimulation, conditional activation, multispecific engineering, and affinity tuning aimed at deepening response rates while mitigating dose-limiting toxicities.
 
Innovation is rife within Korea, with companies such as ABL Bio, Novelty Nobility, ABION, and IM Biologics capturing international attention and investment, positioning Korea as a key player in the bispecific and TCE revolution.
 
To accelerate this momentum, the inaugural World Bispecific and T-Cell Engager Summit South Korea comes as the only event in Asia dedicated to bringing together biopharma professionals focused on the discovery and development of differentiated Bispecifics and T-cell engagers that could become first-in-class therapies. Featuring key international opinion leaders, the agenda will deep dive into co-stimulation techniques, conditional activation, affinity window engineering, and bispecific ADCs (bsADCs), spotlighting cutting-edge strategies to expand the therapeutic window, overcome antigen escape, reduce CRS, and improve clinical predictability.
 
As part of the World Targeted Therapeutics Summit South Korea, organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), targeted protein degradation, and induced proximity, which aim to turn South Korea into the next global hub for biopharma innovation in targeted therapeutics. From discovery to manufacturing, you'll get end-to-end coverage to equip your entire team with the insights needed to innovate and differentiate, ultimately attract interest for global pharma partnerships.